Press Release Contact

Press release:
VRG Therapeutics demonstrates in vivo efficacy with a selective Kv1.3 inhibitor developed for autoimmune diseases
May 26, 2023, 05:00 GMT

For questions about this press release, please contact the person or organization listed below.

Zalan Peterfi
VRG Therapeutics
Visit us on social media:
LinkedIn